Antiglaucoma EP2 Agonists: A long road that led somewhere

David F. Woodward, Jenny W. Wang, W. Daniel Stamer, E. Lütjen-Drecoll, Achim H.P. Krauss, Carol B. Toris

Research output: Contribution to journalReview article

Abstract

For >2 decades, EP2 agonists have been the subject of antiglaucoma research and development by scientists in industry and academia around the world. The road has led to the recent approval of the first drug of this class. This article reviews the development of EP2 agonists from conception to clinical approval, discussing pharmacology, structure, biodistribution, therapeutics, and drug delivery. An extensive list of source references is provided for the reader's benefit.

Original languageEnglish (US)
Pages (from-to)469-474
Number of pages6
JournalJournal of Ocular Pharmacology and Therapeutics
Volume35
Issue number9
DOIs
StatePublished - Nov 2019

Fingerprint

Drug Approval
Industry
Pharmacology
Research
Pharmaceutical Preparations
Therapeutics

Keywords

  • EP agonists
  • drug delivery
  • glaucoma therapy

ASJC Scopus subject areas

  • Ophthalmology
  • Pharmacology
  • Pharmacology (medical)

Cite this

Woodward, D. F., Wang, J. W., Stamer, W. D., Lütjen-Drecoll, E., Krauss, A. H. P., & Toris, C. B. (2019). Antiglaucoma EP2 Agonists: A long road that led somewhere. Journal of Ocular Pharmacology and Therapeutics, 35(9), 469-474. https://doi.org/10.1089/jop.2019.0041

Antiglaucoma EP2 Agonists : A long road that led somewhere. / Woodward, David F.; Wang, Jenny W.; Stamer, W. Daniel; Lütjen-Drecoll, E.; Krauss, Achim H.P.; Toris, Carol B.

In: Journal of Ocular Pharmacology and Therapeutics, Vol. 35, No. 9, 11.2019, p. 469-474.

Research output: Contribution to journalReview article

Woodward, DF, Wang, JW, Stamer, WD, Lütjen-Drecoll, E, Krauss, AHP & Toris, CB 2019, 'Antiglaucoma EP2 Agonists: A long road that led somewhere', Journal of Ocular Pharmacology and Therapeutics, vol. 35, no. 9, pp. 469-474. https://doi.org/10.1089/jop.2019.0041
Woodward, David F. ; Wang, Jenny W. ; Stamer, W. Daniel ; Lütjen-Drecoll, E. ; Krauss, Achim H.P. ; Toris, Carol B. / Antiglaucoma EP2 Agonists : A long road that led somewhere. In: Journal of Ocular Pharmacology and Therapeutics. 2019 ; Vol. 35, No. 9. pp. 469-474.
@article{ac685a0b6a0642b48b2cb3cd7e60243c,
title = "Antiglaucoma EP2 Agonists: A long road that led somewhere",
abstract = "For >2 decades, EP2 agonists have been the subject of antiglaucoma research and development by scientists in industry and academia around the world. The road has led to the recent approval of the first drug of this class. This article reviews the development of EP2 agonists from conception to clinical approval, discussing pharmacology, structure, biodistribution, therapeutics, and drug delivery. An extensive list of source references is provided for the reader's benefit.",
keywords = "EP agonists, drug delivery, glaucoma therapy",
author = "Woodward, {David F.} and Wang, {Jenny W.} and Stamer, {W. Daniel} and E. L{\"u}tjen-Drecoll and Krauss, {Achim H.P.} and Toris, {Carol B.}",
year = "2019",
month = "11",
doi = "10.1089/jop.2019.0041",
language = "English (US)",
volume = "35",
pages = "469--474",
journal = "Journal of Ocular Pharmacology and Therapeutics",
issn = "1080-7683",
publisher = "Mary Ann Liebert Inc.",
number = "9",

}

TY - JOUR

T1 - Antiglaucoma EP2 Agonists

T2 - A long road that led somewhere

AU - Woodward, David F.

AU - Wang, Jenny W.

AU - Stamer, W. Daniel

AU - Lütjen-Drecoll, E.

AU - Krauss, Achim H.P.

AU - Toris, Carol B.

PY - 2019/11

Y1 - 2019/11

N2 - For >2 decades, EP2 agonists have been the subject of antiglaucoma research and development by scientists in industry and academia around the world. The road has led to the recent approval of the first drug of this class. This article reviews the development of EP2 agonists from conception to clinical approval, discussing pharmacology, structure, biodistribution, therapeutics, and drug delivery. An extensive list of source references is provided for the reader's benefit.

AB - For >2 decades, EP2 agonists have been the subject of antiglaucoma research and development by scientists in industry and academia around the world. The road has led to the recent approval of the first drug of this class. This article reviews the development of EP2 agonists from conception to clinical approval, discussing pharmacology, structure, biodistribution, therapeutics, and drug delivery. An extensive list of source references is provided for the reader's benefit.

KW - EP agonists

KW - drug delivery

KW - glaucoma therapy

UR - http://www.scopus.com/inward/record.url?scp=85074445049&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074445049&partnerID=8YFLogxK

U2 - 10.1089/jop.2019.0041

DO - 10.1089/jop.2019.0041

M3 - Review article

C2 - 31329508

AN - SCOPUS:85074445049

VL - 35

SP - 469

EP - 474

JO - Journal of Ocular Pharmacology and Therapeutics

JF - Journal of Ocular Pharmacology and Therapeutics

SN - 1080-7683

IS - 9

ER -